Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMX5SG7)

Drug Name

AZD1772//RDX5791 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic kidney disease	GB61	Phase 2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/hydrogen exchanger 3 (SLC9A3)	TTFZVPO	SL9A3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Sodium/hydrogen exchanger 3 (SLC9A3)	DTT	SLC9A3	2.202	2.678	4.154	2.406

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Chronic kidney disease

ICD Disease Classification

GB61

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Sodium/hydrogen exchanger 3 (SLC9A3)	DTT	SLC9A3	6.83E-01	-0.03	-0.13

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of Ardelyx.
2	RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.